Cat. No. 2691
Alternative Name: RS 10085
Chemical Name: 2-[(2S)-2-[[(1S)-1-(Ethoxycarbonyl)
Biological ActivityAngiotensin-converting enzyme (ACE) inhibitor that is hydrolyzed in the liver to the active metabolite moexiprilat (IC50 values are 2.1 and 2700 nM for moexiprilat and moexipril respectively). Antihypertensive; decreases mean blood pressure in the spontaneous hypertensive rat (SHR). Also blocks degradation of bradykinin into inactive metabolites.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Product Datasheet / Safety Data Sheet
Chrysant and Chrysant (2004) Pharmacological and clinical profile of moexipril: a concise review. J.Clin.Pharmacol. 44 827. PMID: 15286086.
Friehe and Ney (1997) Pharmacological and toxicological studies of the new angiotensin converting enzyme inhibitor moexipril hydrochloride. Arzneim.-Forsch. 47 132.
Edling et al (1995) Moexipril, a new angiotensin-converting enzyme (ACE) inhibitor: pharmacological characterization and comparison with enalapril. J.Pharmacol.Exp.Ther. 275 854. PMID: 7473177.
If you know of a relevant reference for this product please let us know.
Citations are publications that use Tocris products.
Do you know of a great paper that uses Moexipril hydrochloride from Tocris? If so please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Moexipril hydrochloride, supplier, Angiotensin-converting, enzyme, ACE, inhibitors, inhibits, Proteinases, Proteases, RS10085, Tocris Bioscience, Angiotensin-Converting Enzyme Inhibitor products
Find multiple products by catalog number
New Products in this Area
Potent 20S proteasome inhibitorDiprotin A
Dipeptidyl peptidase IV (DPP-IV) inhibitorAcein
High affinity angiotensin-converting enzyme (ACE) ligandTMI 1
Adam 17 (TACE) and MMP inhibitor; orally bioavailableRitonavir
HIV-1 and HIV-2 protease inhibitor
One Day Symposium
March 1, 2017
Amsterdam, The Netherlands